These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 19528449

  • 1. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
    Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, Faure M, Kanitakis J.
    Anticancer Res; 2009 Jun; 29(6):1927-32. PubMed ID: 19528449
    [Abstract] [Full Text] [Related]

  • 2. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 3. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 4. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.
    Clin Transplant; 2009 Aug 27; 23(3):351-60. PubMed ID: 19208105
    [Abstract] [Full Text] [Related]

  • 5. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 27; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients.
    Diekmann F, Fritsche L, Neumayer HH, Budde K.
    Kidney Blood Press Res; 2004 Jun 27; 27(3):186-90. PubMed ID: 15256816
    [Abstract] [Full Text] [Related]

  • 7. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Jun 27; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 8. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E.
    Liver Transpl; 2007 May 27; 13(5):658-64. PubMed ID: 17457887
    [Abstract] [Full Text] [Related]

  • 9. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
    Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J, TUMORAPA Study Group.
    N Engl J Med; 2012 Jul 26; 367(4):329-39. PubMed ID: 22830463
    [Abstract] [Full Text] [Related]

  • 10. The role and value of sirolimus administration in kidney and liver transplantation.
    Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J.
    Clin Transplant; 2006 Jul 26; 20 Suppl 17():30-43. PubMed ID: 17100699
    [Abstract] [Full Text] [Related]

  • 11. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May 27; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 14. Conversion to sirolimus in renal transplant patients with tumors.
    Sánchez-Fructuoso A, Conesa J, Perez Flores I, Ridao N, Calvo N, Prats D, Rodríguez A, Barrientos A.
    Transplant Proc; 2006 Oct 27; 38(8):2451-2. PubMed ID: 17097964
    [Abstract] [Full Text] [Related]

  • 15. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.
    Euvrard S, Boissonnat P, Roussoulières A, Kanitakis J, Decullier E, Claudy A, Sebbag L.
    Transpl Int; 2010 Aug 27; 23(8):855-7. PubMed ID: 19951373
    [No Abstract] [Full Text] [Related]

  • 16. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.
    J Am Soc Nephrol; 2006 Feb 27; 17(2):581-9. PubMed ID: 16434506
    [Abstract] [Full Text] [Related]

  • 17. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V, Gutierrez C, Cabello M, Burgos D, Sola E, Gonzalez-Molina M.
    Transplant Proc; 2007 Sep 27; 39(7):2264-6. PubMed ID: 17889158
    [Abstract] [Full Text] [Related]

  • 18. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F, Di Sandro S, De Ruvo N, Spaggiari M, Montalti R, Ballarin R, Cappelli G, Gerunda GE.
    J Clin Gastroenterol; 2009 Mar 27; 43(3):280-6. PubMed ID: 19057397
    [Abstract] [Full Text] [Related]

  • 19. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
    Teutonico A, Schena PF, Di Paolo S.
    J Am Soc Nephrol; 2005 Oct 27; 16(10):3128-35. PubMed ID: 16107580
    [Abstract] [Full Text] [Related]

  • 20. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M, Zegarska J, Pawłowska M, Wyzgał J, Ciszek M, Paczek L.
    Transpl Immunol; 2009 Jan 27; 20(3):139-42. PubMed ID: 18834941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.